UPC starts scientific research on the quality of medical cannabis in the Peruvian market

The Peruvian University of Applied Sciences together with Futura Farms, a company dedicated to the development of cannabis products, will carry out scientific research on products made from medical cannabis that are currently on the Peruvian market.

The latest CBD & Cannabis updates are now at your fingertips, with notifications and fresh information offered by our companion CBD News App. Stay up-to-date with marijuana stocks for investments, global market, cannabis legalization and more.

The first study of cannabis product quality in the Peruvian market

The first study to be carried out by both institutions aims to gather specialized information from the Peruvian market on the quality of cannabis products, the benefits they offer to patients and their consistency, among other attributes.

“The academy has to bet on this type of research to guarantee the quality of the products that thousands of Peruvians have been consuming. The medical cannabis market is growing by leaps and bounds and the potential for development is very large,” said Raul Injoque, academic director of the Agribusiness career at the UPC.

On his part, Jose Ignacio Escalante, general manager of Futura Farms, pointed out that this is the first research they are carrying out together with the academy in order to contribute with real information about the national market. “The opportunities are very wide and the universities are betting on it,” said the executive.

The global medical cannabis market is set to grow

On this occasion, the UPC, through the School of Agribusiness, will provide the resources of the Research Center where they have different specialists in the sector, while Futura Farms will provide the expertise of the business.

It should be mentioned that, following the publication of Law 30681 regulating the medical and therapeutic use of cannabis and its derivatives, Peru is an attractive market for a number of investors who see this sector as a big opportunity. According to the Ministry of Health (Minsa), at the moment cannabis is needed by more than seven thousand Peruvians.

The growth potential of the global medical cannabis sector is impressive. Europe is set to be the focus of the boom with a market that could be worth $132 billion by 2023, assuming all European nations legislate for legalized cannabis.

Market surveys, like the one conducted in Peru, will be an important component of this growth. Medical cannabis needs to meet incredibly high standards in order to satisfy doctors and they will refer back to studies undertaken in other jurisdictions.

__

(Featured image by skeeze via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in elEconomista, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.